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Summary The ability of essential fatty acids (EFAs) to modulate radiation-induced normal tissue injury was
assessed in pig skin. Female Large White pigs (-25 Kg) received 3 ml/day orally of either an 'active' oil
[So-I 100, containing 9% gamma-linolenic acid (GLA)] or a 'placebo' oil (So-1 129) for just 4 weeks before or
for 4 weeks before and for 16 weeks after irradiation; localised irradiation of skin was with single doses of
P-rays from 22.5 mm diameter 9"Sr/9Y plaques. The severity of the acute reaction, assessed in terms of
erythema or moist desquamation, was significantly less in those pigs that received So-l 100 both before and
after irradiation, as compared with those receiving that oil only prior to irradiation and the 'placebo' groups.
Dose modification factors (DMFs) of between 1.13-1.24 were obtained. A similar reduction in the severity of
acute skin injury was seen in pigs receiving So-1100 for only 10 weeks after irradiation. Late skin damage,
assessed in terms of late erythema or dermal necrosis, was also reduced with So-l100, with DMFs of
1.14-1.51. No such modification was observed if So-1100 was only administered for 4 weeks prior to
irradiation. No adverse side-effects were apparent as a result of EFA administration. So-l 100 may represent a
safe and valuable method of increasing the therapeutic gain in radiotherapy.
In radiotherapy the dose that can be administered to a
tumour is limited by the risk of early or late morbidity to
those normal tissues included within the treatment volume.
Several approaches, in addition to modifications in fractiona-
tion schedules, have been used in an attempt to improve the
therapeutic ratio. In general, these have focused on, either
the enhancement of tumour cell radiosensitivity by overcom-
ing the problem of hypoxia, using sensitisers, or the selective
protection of normal tissues using radioprotectors. Such ap-
proaches have achieved limited success (Overgaard et al.,
1992; Dische, 1992) and have often been hampered by prob-
lems of agent-associated toxicity (Blumberg et al., 1982;
Overgaard et al., 1989).
An alternative approach is to utilise interventional pro-
cedures after radiation exposure, which are directed at sel-
ectively reducing the severity of normal tissue morbidity
without comprising tumour cell kill. Such as approach, using
various biological response modulators (BRMs), could bring
significant clinical benefits. Recent studies wtih various
agents, which might be termed BRMs, have demonstrated
significant amelioration of radiation-induced normal tissue
morbidity. These include the use of Captopril an angiotensin
converting enzyme inhibitor (ACE), effective in reducing
radiation damage to skin (Ward et al., 1990), lung (Ward et
al., 1992) and kidney (Robbins & Hopewell, 1986); Dipyrimi-
dazole and Desferrioxamine in the spinal cord (Hornsey et
al., 1990), and Pentoxifylline (PTX) in cutaneous tissue (Dion
et al., 1989). PTX has been shown to be of significant clinical
benefit in the treatment of late-induced radiation soft tissue
necrosis (Dion et al., 1990).
The precise mode of action of individual BRMs remains
uncertain, however, there is a growing realisation that the
development of radiation-induced normal tissue morbidity
reflects a cascade of complex events in which both direct and
indirect effects of radiation on cells results, ultimately, in the
expression of organ damage. These events include alterations
in eicosanoid metabolism. In vitro and in vivo studies of
radiation effects on the vasculature indicate an initial increase
in prostacyclin (PGI2) production followed by a long-term
reduction; this can last for ) 12 months (Sinzinger et al.,
1984; Eldor et al., 1989; Rubin et al., 1991). Thromboxane
(TXA2) production appears to be unaffected (Allen et al.,
1981). A similar imbalance in the ratio of these two dienoic
eicosanoids has been reported in vivo following irradiation of
the kidney (Schneidkraut et al., 1984; Weshler et al., 1987)
and the lung (Ward et al., 1990). Moreover, increases in
prostaglandins (PGs) and inflammatory mediators, (leuko-
trienes-LTs), have also been reported in the gut and oral
mucosa (Abdelaal et al., 1989; Cole et al., 1993) after irradia-
tion.
Although there is a tendency to assume that the EFAs are
important only as precursors of eicosanoids, their most
important role is related to the structure of membranes,
where they regulate membrane fluidity and flexibility and the
functions ofmembrane related proteins such as receptors, ion
channels, ATPases and the proteins associated with secon-
dary messenger systems (Horrobin, 1992). Therefore, it is
possible that the loss of EFAs themselves may be a major
factor in the development of radiation-induced damage to
normal tissues (Horrobin, 1991; Stark, 1991).
The above findings suggest that the prevention of altera-
tions in eicosanoid and EFA metabolism could lead to a
reduction in normal tissue morbidity. Indeed, the direct use
of exogenous PGs and/or inhibitors of PG production, such
as indomethacin, have proved beneficial (Tochner et al.,
1990). However, an alternative approach appears to be the
modification of essential fatty acid (EFA) levels, the precur-
sors of eicosanoids (Willis, 1981). Administration of gamma-
linolenic acid (GLA) has been shown to result in an in-
creased production of the monoenoic PGE, rather than
dienoic PGs such as PGE2 and TXA2. Moreover, GLA itself
leads to the formation of 15-OH-dihomogammalinolenic
acid, an inhibitor of LT formation (Horrobin & Manku,
1990). PGE, has a number of desirable physiological actions
(Zurier, 1990); these include anti-inflammatory, anti-aggre-
gatory, and vasodilatory activity.
Although the main essential fatty acid in the diet is linoleic
acid, the most important constituents of all membranes are
the linoleic acid metabolites dihomogammalinolenic acid
(DGLA) and arachidonic acid (AA). Conversion of linoleic
acid to its first metabolite, GLA, is slow and rate limiting,
especially in humans. In the present study the properties of
an oil containing linoleic acid (So-1129) with an oil contain-
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ing linoleic acid and GLA (So-I 100) are compared. The
difference between the two oils allows an evaluation of the
role of EFA metabolites in modulating radiation-induced
damage.
To assess the ability of EFAs to ameliorate radiation-
induced normal tissue injury the effects of So-1100 on acute
and late radiation responses in pig skin were assessed. These
skin responses were compared with those observed in pigs
receiving a 'placebo' oil So-i 129 (oil containing 79% LA and
no GLA). In order to resolve whether GLA might act as a
radioprotector rather than a BRM these oils were given
either up to the time of irradiation only or both before and
after irradiation. PGs have been reported to protect against
radiation damage (Hanson & Ainsworth, 1985). EFA admin-
istration was initiated 4 weeks prior to irradiation to ensure
stable EFA levels in the animals before local skin irradiation.
The pig is the ideal laboratory animal for such studies, as pig
and human skin are essentially identical in terms of their
structure and response to radiation (Hopewell, 1986). Fur-
thermore, the assay systems used produce highly reproducible
data (Hopewell & van den Aardweg, 1988).
Materials and methods
A total of 16 female pigs of the Large White strain were used
in these investigations. Animals were approximately 12 weeks
of age (20-25 kg) when they were brought into the animal
house and were allowed an acclimatisation period of 2 weeks
prior to any experimental procedures being carried out. A
group of 12 pigs then received oils orally, 3 ml/day for 4
weeks. Administration of oil was via a syringe so that the oil
could be directed towards the back of the oral cavity. These
animals were randomly allocated to either what was termed
an 'active' oil (So-i 100, containing 9% GLA) or to a
'placebo' oil (So-1129, Sunflower oil). The main difference
between these two oils is that there is 9% GLA in So- 1100
and no GLA in So-1129. Otherwise the fatty acid composi-
tions are not dissimilar (Table I). The remaining four pigs
received no oils over this period.
Three weeks from the start of administration of the oils
and 1 week prior to irradiation the skin sites to be irradiated,
16 per flank, were marked out by tattooing with India ink.
These sites were 25 mm in diameter with 40 mm between
sites. Subsequent irradiation was with single doses of P-rays
from 22.5 diameter 'Sr/9Y plaques (Amersham Inter-
national, UK). Skin surface doses (measured at 16gim depth)
were given at a rate of -3.0 Gy/min. For animals given the
'active' oil, total doses in the range 20-40 Gy were used;
doses of 20-34 Gy were used for the 'placebo' group. In
each treatment group 5 different radiation dose levels were
used; 10-12 sites were irradiated to each dose at randomly
selected skin fields. For all the experimental procedures the
pigs were anaesthetised with a mixture of -70% oxygen,
-30% nitrous oxide and 2% halothane (Dickinson & Hub-
bard, 1990).
At the time of irradiation daily administration of oils was
discontinued in four of the 12 pigs (two 'active'; two 'pla-
cebo'), the remaining eight pigs (six 'active'; two 'placebo')
continued to receive oil at 3 ml/day for a further 16 weeks.
The four pigs that had received no oil prior to irradiation,
Table I Composition of the fatty acids used in the studies described
in this paper
So-1129 So-i100
Linoleic (18:2n-6) 79.0 70.2
Gamma-linolenic (18:3n-6) - 8.7
Oleic (18:1n-9) 10.7 12.7
Stearic (18:0) 2.1 1.8
Palmitic (16:0) 6.9 5.8
Alpha-linolenic (18:3n-3) 0.6
Others 0.7 0.8
were given it at the same dose (two 'active'; two 'placebo')
for a period of 10 weeks after irradiation.
To assess the severity of the early skin reactions the
irradiated skin sites were examined at weekly intervals for 10
weeks by at least 3 observers. Erythema was evaluated as
being either minimal (A), moderate (B) or bright red (C) and
the sites were also assessed as to the presence or absence of
moist desquamation (van den Aardweg et al., 1988). Dose-
related changes in the skin response were initially evaluated
on the basis of the ordinal data for erythema by calculating,
for each dose level, an average erythema score over the
period 3-9 weeks after irradiation. For this purpose an
arbitrary numerical score was assigned to the different visual
observations (Hopewell et al., 1978) and dose-effect curves
fitted by linear regression analysis. Different treatment sche-
dules were compared on the basis of an average score of 1.5
obtained from the dose-effect curves. Alternatively, responses
were converted into quantal data by assessing the dose-
related changes in the percentage of skin sites that showed,
over the time course of the acute reaction: (a) > moderate
erythema; (b): bright red erythema; or (c) moist desquama-
tion. These quantal data were analysed using probit analysis
and ED50 (± s.e.) values calculated in order to compare
different treatment schedules.
In the eight pigs that received oil (six 'active'; two 'pla-
cebo') for a period up to 16 weeks after irradiation, and the
four animals that only received oils (two 'active'; two 'pla-
cebo') up until the time or irradiation, the skin reactions
were assessed for a further period of 6 weeks (weeks 10-16).
The severity of the later dermal reaction in these animals was
compared on the basis of the dose-related incidence ofdusky/
mauve erythema and of dermal necrosis (van den Aardweg et
al., 1988).
Results
Daily oral administration of oils (both the 'active' and
'placebo') was achieved without difficulty, the animals accep-
ting these prior to normal feeding early each morning.
Administration of the 'active' oil, even over a prolonged
period of 20 weeks, appeared to have no adverse effects on
the general condition of the animals. The increase in weight
of the two pigs which received the 'placebo' oil for a full 20
weeks was within the same range as those receiving the
'active' agent (Figure 1).
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Figure 1 Time-related changes in the body weight (± s.d.) of
pigs receiving the 'active' oil, So-I 100 (-*) for4 weeks prior to
and for 16 weeks after local skin irradiation. The individual body
weight values for the two pigs receiving the 'placebo' oil, So-
1129, (A,A) are given for comparison.
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The dose-related changes in the average erythema scores,
obtained 3-9 weeks after irradiation, for pigs that only
received oils for the 4 weeks prior to irradiation are shown in
Figure 2a. Separate linear-dose-response curves have been
fitted to the data for the 'active' (So-1100) and the 'placebo'
(So-1129) oil. For doses in the range 20-40 Gy, average
erythema scores varied from 1.2-2.2 arbitrary units. Based
on an average erythema score of 1.5, iso-effect doses of
21.4 ± 1.4 Gy and 26.5 ± 1.6 Gy were obtained for the 'act-
ive' and 'placebo' groups, respectively. This difference was
statistically significant (P<0.02) suggesting a slight enhance-
ment of the radiation response by the 'active' oil [dose
modification factor (DMF) = 0.81 ± 0.07].
A similar set of data for four pigs receiving oils both prior
to and after irradiation are illustrated in Figure 2b. These
animals were irradiated at the same time and their reactions
assessed over the same time period as those animals the
results for which are shown in Figure 2a. The most obvious
feature is that the average erythema scores are lower (range
0.6-1.6) in those pigs receiving oils after irradiation and over
the time course of the radiation response. The iso-effect doses
based on an average erythema score of 1.5, were 37.1 +
2.4 Gy and 30.7 ± 2.2 Gy for the 'active' and 'placebo'
groups, respectively. These iso-effect doses were significantly
different (P<0.05). This suggested a DMF of 1.21 ± 0.12.
The higher iso-effect dose obtained for the 'placebo' group
when the oil was given both before and after irradiation
(30.7 ± 2.2 Gy) as compared with only prior to irradiation
(26.5 1.0 Gy) was not statistically significant (P>0.05).
However, the degree of modification in the radiation re-
sponse on the above plots appears to be a function of the
severity of the reaction and is also subject to the assumption
that the relationship between average skin score, based on an
arbitrary scale, and dose is linear.
In view of these concerns, these data and the observations
from subsequent animals were transformed into quantal data
in order to establish dose-effect relationships for > moderate
erythema () B) and bright red (C) erythema. A skin site was
adjudged to represent a responder if more than half of the
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observers assessed the reaction as being either > B or C in
any single week over the period of the early reaction.
The ED50 values for the different severities oferythema for
the various treatment groups are listed in Table II. An
illustrative dose-effect curve for the incidence of bright red
erythema is shown in Figure 3. In this figure data for the two
'placebo' groups, i.e. So-i 129 given either only prior to
irradiation or before and after irradiation, have been com-
bined, since the radiation response of the two groups was
similar. The ED50 values (± s.e.) were 29.68 ± 1.68 Gy and
31.76 ± 1.39 Gy, respectively (P>0.45). A similar conclusion
was reached on the basis of comparing the ED50 values for
> B grade erythema. However, the ED50 values for > B and
C grade erythema for the group of pigs receiving So-1129
both before and after irradiation, was higher (-11%) than
that for those receiving this oil only prior to irradiation. This
trend was again repeated in the group that only received
So-1129 after irradiation; in this case the difference in the
ED50 values for C grade erythema approached statistical
significance (P<0.1 >0.05).
The dose-effect curves for the incidence of bright red
erythema (Figure 3) illustrate the marked difference in res-
ponse observed when So-1100 was given both before and
after irradiation as compared with before irradiation only.
The response following administration of So-1129, the pla-
cebo, was somewhat intermediate between the two. When
ED50 values for both C and > B grade erythema after So-
1100 administration were compared with the associated re-
sults for the 'placebo' group a dose modification factor of
t 1.2 (P<0.005) was obtained for the before and after
irradiation group. No significant change in response was seen
when So-I 00 was given only prior to irradiation (P> 0.1)
(Table II). The suggestion that to be effective So-I 100 has to
be given over the time course of the early radiation response
is supported by the results from the group of pigs that
received oils only after irradiation. A dose modification fac-
tor of 1.2 ± 0.14 was obtained for the incidence of a C grade
erythema (P<0.1 >0.05) in these studies. No significant
modification was noted based on the end point of a > B
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Figure 2 Dose-related changes in the erythema scores in pig skin averaged over the period 3-9 weeks after irradiation with single
doses of `Sr/PY frrays. Results are for animals receiving EFAs either for 4 weeks prior to irradiation a, or for 4 weeks prior to
irradiation and 16 weeks after irradiation b. Animals received either the 'active' oil, So-I 100 (0), or the 'placebo' oil, So-I 129 (0). Error bars indicate ± s.e.
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Table II Variation in ED50 values for different seventies oferythema in pig skin after
irradiation with single doses of'Sr/9Y P-rays and pre- and post-irradiation treatment
with oils (So- 1100 and So-1129)
Treatment period Severity ED50 ± s.e. (Gy)
(weeks) of reaction So-ilOO So-1129 DMF
-4 C 26.81 ± 1.15 29.68 1.68 NS
>, B <<«20 20.35 1.29 -
- 4/+ 16 C 39.23 0.98 31.76 1.39 1.24 0.06
> B 26.46 ± 0.79 22.66 ± 0.69 1.17 ± 0.05
+ 10 C 41.16 3.79 34.44 2.35 1.2 ±0.14
> B 23.34 ± 2.28 22.49 ± 1.96 NS
NS = no significant dose modification
E
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Figure 3 Dose-related changes in the incidence of bright red
erythema in pig skin after irradiation with single doses of 90Sr/90Y
P-rays. Animals received an 'active' oil, So-1100, for either 4
weeks prior (0) or for 4 weeks prior and 16 weeks after irradia-
tion (0) or a 'placebo' oil, So-i 129 both before and after irradia-
tion (0). ED50 values ( ± s.e.) are indicated.
grade erythema. However, the data from this group of
animals showed considerably greater scatter than those from
other groups. Based on the results for the incidence of C
grade erythema, the degree of modification produced by So-
1100 given both before and after irradiation was similar to
that seen when it was only given after irradiation.
The results obtained based on the endpoint of moist des-
quamation are shown in Table III. In the pigs receiving oils
for only 4 weeks prior to irradiation the ED50 values were
both -27 Gy, not significantly different from historical data
for pig skin when irradiation was carried out without the
administration of oils (Hopewell & van den Aardweg, 1988).
The administration of oils, both 'active' and 'placebo', over
the time course of the radiation reaction resulted in higher
ED50 values for moist desquamation. They were significantly
higher (P<0.05) except for the 'placebo' group (- 4/ + 16
weeks). In the case of the groups receiving oils both prior to
and after irradiation the difference in ED50 values for moist
desquamation between the 'active' and 'placebo' was highly
significant (P<0.005) suggesting a DMF of 1.13 ± 0.05.
Table III Iso-effect doses (ED50) for moist desquamation in pig skin
after pre- or post-irradiation treatment with So-1 100 ('active') or
So-1129 ('placebo') oils
Treatment period ED50 ± s.e (Gy)
(weeks) So-llOO So-1129 DMF
-4 26.00 1.87 27.91 1.15 NS
- 4/+ 16 33.81 + 0.8 30.04 1.18 1.13 ± 0.05
+ 10 31.74±1.08 31.03 1.42 NS
Historical control ED50 ( s.e.) values for moist desquamation
27.32 ± 0.5 Gy (Hopewell & van den Aardweg, 1988).
The modification in the severity of the early skin reaction
of moist desquamation, and the possible effect of the 'pla-
cebo' agent when given over the time course of the early skin
reaction, was supported by the observations on the duration
ofmoist desquamation for specific dose levels above the ED50
(Table IVa). For single doses in the range 28-32 Gy the
healing times for moist desquamation were in the order of
2.7-3.7 weeks when the oils were only given prior to irradia-
tion. Extending the administration of the oils over the period
associated with the development of moist desquamation
reduced this to 2.2 weeks for the 'placebo' group and to only
1.2 weeks for the 'active' oil. However, the time of onset of
moist desquamation was not influenced by the continued
administration of oils over the period of the early reaction
(Table IVb).
For the assessment of late, vascular mediated, lesions in
pig skin the incidence of a second wave of dusky/mauve
erythema and ischaemic necrosis was assessed 10-16 weeks
after irradiation. The ED50 values for these two dermal reac-
tions are given in Table V. Prior treatment with So-1100 did
not significantly modify the responses with respect to those
seen after a similar treatment with So-1129. The administra-
tion of So-1129 over the time course of the reaction also
produced no further changes in the severity of the reaction.
However, administration of So-1100 over the time course of
the late dermal reaction significantly reduced its severity;
DMFs of 1.14 ± 0.06 and 1.51 ± 0.12 were obtained for nec-
rosis and dusky/mauve erythema, respectively.
Discussion
The present findings clearly demonstrate that the administra-
tion of EFA metabolites had a significant effect on both the
acute and late radiation responses of pig skin. The nature of
these effects was dependent on the particular EFA dose
regimen used. Thus in animals that received So-1100 or the
'placebo' So-1129 for 4 weeks up to the time of irradiation
alone there was no evidence of any reduction in the severity
of the radiation-induced skin damage. Indeed, analysis of
Table IV Time of onset and duration of moist desquamation in pig
skin irradiation with single doses of 90Sr/9Y P-rays
(A) Duration moist desquamation (weeks; mean ± s.e)
Treatment Dose Dose
(weeks) (Gy) So-llOO (Gy) So-1129
-4 28 2.7 1.1 29 3.4± 1.0
32 3.1 ±0.7 31 3.7 ± 0.7
-4/+ 16 28 1.3±0.3 29 2.2±0.6
32 1.2 0.2 31 2.2 0.7
(B) Onset of moist desquamation (weeks; mean ± s.e)
Treatment Dose Dose
(weeks) (Gy) So-llOO (Gy) So-1129
-4 28 4.7±0.2 29 5.2±0.5
32 4.4±0.3 31 4.5±0.3
-4/+ 16 28 5.0±0.6 29 5.2±0.4
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Table V Iso-effect doses (ED50) for both dermal necrosis (N) or dusky/mauve
erythema (E) in pig skin after pre- and post-irradiation treatments with So-1100
('active') or So-1129 ('placebo') oils
Treatment period Type of ED50 ± s.e. (Gy)
(weeks) reaction So-ilOO So-1129 DMF
-4 N 34.8 1.4 35.0 1.5 NS
E 26.5 1.3 27.5 1.1 NS
-4/+ 16 N 40.6 1.3 35.7 1.6 1.14±0.06
E 37.5 1.9 24.8 1.5 1.51 0.12
average erythema scores inferred a slight enhancement of the
acute skin response in those pigs receiving So-I 100. However,
no such enhancement was evident for either acute radiation
damage, assessed in terms of the incidence of moist des-
quamation, or for the later radiation damage to dermal
tissues, assessed in terms of the incidence of dusky mauve
erythema or dermal necrosis. In contrast, administration of
So-I 100 from 4 weeks prior to irradiation and for the follow-
ing 16 weeks after irradiation resulted in a significant reduc-
tion in the severity of skin damage compared with that seen
in pigs which received So-1129 over a similar time-course.
DMF values in the order of 1.2 and 1.13 were obtained for
the early responses of bright-red erythema and moist des-
quamation, respectively. These findings indicate that So-i 100
significantly reduces the severity of acute radiation-induced
morbidity in pig skin when administered over the time-course
of the reaction. A similar trend was noted in pigs receiving
So-1100 for 10 weeks after irradiation alone. It should be
noted that administering the 'placebo' oil So-1129 before and
after irradiation did in itself increase the ED50 value for moist
desquamation compared with that seen in historical control
animals (Hopewell & Aardweg, 1988). Thus comparing the
ED50 value for moist desquamation for pigs receiving So-
1100 both before and after irradiation with that from histor-
ical control animals resulted in a significantly increased DMF
value of 1.24 ± 0.04 (P<0.001), an indication as to some
effect of the 'placebo' oil, So-1129.
The reduction in the severity of moist desquamation pro-
duced by So-I 100 was also evident in terms of a reduction in
the duration, but not the time of onset, of moist desquama-
tion. The healing times for moist desquamation of some 3-4
weeks observed in the pigs receiving EFAs prior to irradia-
tion alone were reduced in pigs receiving So-II00 or So-1129
both before and after irradiation to approximately 1 and 2
weeks, respectively. The mechanism(s) responsible for this
enhanced healing response remains unclear. It may reflect, at
least in part, an induced acceleration of epithelial cell turn-
over by EFAs. Preliminary observations from biopsies of
skin taken from pigs receiving EFAs have shown a marked
increase in the labelling index of basal cells and an increase
in the number of viable cell layers, indicating an increase in
cell proliferation kinetics (Morris et al., unpublished data).
This could occur via an EFA-induced increase in PGE,
production; exogenous PGE1 has been shown to accelerate
gastrointestinal repair by increasing cell proliferation rates
(Levi et al., 1990). It may also reflect a direct action of EFAs
which are required for membrane synthesis in proliferating
cells.
The administration of So-I100 before and after irradiation
also resulted in a significant reduction in the severity of late
vascular mediated lesions in pig skin i.e. dusky/mauve ery-
thema and dermal necrosis. As seen for the acute reactions,
the modification in the response was greater for the erythe-
matous reaction than for necrosis; the DMFs were approxi-
mately 1.5 and 1.2, respectively. No modification of late
damage was evident in animals receiving EFAs only prior to
irradiation, or in those receiving So-1129 both before and
after irradiation. The greater modification of the erythema-
tous reaction than the more severe reactions of moist des-
quamation and dermal necrosis is of interest and suggests a
greater ability of GLA to modify the inflammatory aspect of
these lesions, possibly through changing membrane structure
or by increased production of PGE, and/or reducing LT
production (Horrobin & Manku, 1990). However, the precise
mode of action remains to be defined. In particular, measure-
ments of possible alterations in EFA, PG and LT levels
occurring as a result of the irradiation of pig skin are
required.
It is important to note the lack of any modifying effect
seen in animals only treated with So-1100 prior to irradia-
tion, indicating that So-1100 afforded no direct radioprotec-
tion. Rather it acts as a BRM in the sense that its presence is
required throughout the time-course of the expression of
early and late damage. The BRMs Captopril and PTX have
also been shown to reduce the severity of late radiation
damage to skin (Ward et al., 1990; Dion et al., 1989). How-
ever, only Captopril appeared to also reduce the severity of
the acute skin response.
The finding that administration of the 'placebo' oil So-
1129 also resulted in some amelioration of the acute radia-
tion-induced skin damage is of interest. It should be noted
that there is little evidence to suggest that So-1129 is a truly
inert 'placebo'. The main EFA constituent of So-i 129 is
linoleic acid (LA); So-1129 contains 79% LA, while So-i 100
contains 70% LA plus 9% GLA (Table I). Administration of
LA to normal humans results in increased levels of both LA
and arachidonic acid (AA), the precursor of the dienoic PGs
(Horrobin et al., 1991). Such an elevation of blood concen-
trations of the potentially pro-inflammatory AA could worsen
clinical disorders in which inflammation, platelet aggregation
and vasoconstriction are important, viz radiation-induced
normal tissue injury. Indeed, administration of So-1129 to
children with atopic eczema did worsen the clinical status of
these patients. However, no such increase in severity of the
acute radiation damage was seen in the pigs receiving So-
1129. There is little information yet available concerning
EFA metabolism in the pig; in particular, the effect of LA or
GLA administration on the blood levels of LA, GLA or AA
has yet to be determined.
The DMFs of between 1.13 to 1.5 for acute and late skin
reactions represent a potentially clinically significant effect,
with in excess of 10% or more dose being required to pro-
duce the same level of normal tissue injury. Such a dose
increment would, for many tumours, provide a significant
improvement in local control by radiotherapy. An important
aspect of using such BRMs is that EFAs can be easily
administered and appear to be non-toxic. In the present
study there were no apparent adverse side-effects associated
with the administration of EFAs over periods of up to 20
weeks. Animal toxicology studies using doses up to 5 ml or
10ml kg/day have also reported no toxic effects attributable
to EFA administration (Everett et al., 1988a; 1988b). More-
over, clinical trials involving the daily administration of very
high doses of GLA for periods up to 1 year have revealed no
significant adverse side-effects (Dodge, 1990).
Thus administration of EFAs appears to offer a potentially
safe way ofreducing the severity ofradiation-induced normal
tissue injury. Recent studies examining the effects of EFAs
on tumour cells would seem to indicate that this reduction in
radiation-induced injury is specific for normal tissues. GLA
administration to co-cultures of normal and malignant cells
from the same tissue results in the killing of malignant cells
within 5-10days ofexposure; normal cells remain unaffected
(Fujiwara et al., 1984; Begin et al., 1986a; 1986b). Further-6 J.W. HOPEWELL et al.
more, in vivo studies have shown that GLA inhibits the
growth of dimethylbenzanthracene-induced mammary tum-
ours in rats (Lee & Sugano, 1986). This GLA-mediated
tumour cytotoxicity may reflect increased lipid peroxidation
resulting in the death of tumour cells (Horrobin, 1990).
However, the effects of So-1100 and So-1129 on tumour
regrowth delay after irradiation have still to be established
although such investigations are now underway (Stratford,
personal communication). Thus it would appear that the use
of EFAs, acting as BRMs, may result in a significant increase
in the therapeutic gain in the treatment of cancer by radio-
therapy.
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